Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan
Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of...
Rare / orphan disease drugs
Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
Roche’s Piasky (Crovalimab) Secures NMPA Approval for Untreated Paroxysmal Nocturnal Hemoglobinuria
The National Medical Products Administration (NMPA) has granted marketing approval to Swiss pharmaceutical giant Roche...
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...
European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy
The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...
Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...
Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates
Boan Biotech (HKG: 6955), a Chinese biotechnology company, has announced that it has received orphan...
Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease
Lingyi Biotechnology Co., Ltd, a China-based gene therapy developer, has secured clinical trial approval from...
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate...
Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001
Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...
HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy
China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...
Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome
Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...
Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development
Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...
Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...
Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...